
DURECT Corporation DRRX
Quartalsbericht 2025-Q2
hinzugefügt 13.08.2025
DURECT Corporation EV 2011-2026 | DRRX
EV Jährlich DURECT Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.37 M | 66.3 M | -35.1 M | 22.8 M | 374 M | 95.9 M | 177 M | 169 M | 171 M | 134 M | 228 M | 91.3 M | 106 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 374 M | -35.1 M | 123 M |
EV anderer Aktien in der Arzneimittelhersteller
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
6.79 M | - | 7.5 % | $ 6.35 M | ||
|
Assertio Holdings
ASRT
|
238 M | $ 18.79 | 0.99 % | $ 120 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
28.5 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
737 M | - | - | $ 754 M | ||
|
Catalent
CTLT
|
16.7 B | - | - | $ 11.5 B | ||
|
Cumberland Pharmaceuticals
CPIX
|
124 M | $ 3.12 | 1.63 % | $ 43.9 M | ||
|
Endo International plc
ENDP
|
-710 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
7.15 M | - | - | $ 36.6 M | ||
|
Agile Therapeutics
AGRX
|
25.3 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
197 M | - | - | $ 142 M | ||
|
Athenex
ATNX
|
209 M | - | -23.39 % | $ 1.76 M | ||
|
Cronos Group
CRON
|
3.84 B | $ 2.56 | 1.59 % | $ 1.33 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
756 M | - | - | $ 2.06 B | ||
|
Jupiter Wellness
JUPW
|
3.7 M | - | - | $ 33.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
10.2 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
284 M | - | 2.45 % | $ 38.1 M | ||
|
Neoleukin Therapeutics
NLTX
|
-80.1 M | - | - | $ 193 M | ||
|
Bausch Health Companies
BHC
|
29.9 B | $ 5.4 | 2.57 % | $ 1.97 B | ||
|
Harrow Health
HROW
|
2.21 B | $ 36.41 | 2.75 % | $ 1.34 B | ||
|
Aurora Cannabis
ACB
|
106 M | $ 3.45 | 2.38 % | $ 86.3 M | ||
|
Canopy Growth Corporation
CGC
|
459 M | $ 1.02 | 3.25 % | $ 110 M | ||
|
PetIQ
PETQ
|
280 M | - | 1.64 % | $ 400 M | ||
|
ProPhase Labs
PRPH
|
145 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
700 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
220 M | - | -4.76 % | $ 65.3 M | ||
|
Eagle Pharmaceuticals
EGRX
|
457 M | - | -39.89 % | $ 27.7 M | ||
|
Organogenesis Holdings
ORGO
|
392 M | $ 2.47 | 9.38 % | $ 325 M | ||
|
Evolus
EOLS
|
467 M | $ 4.13 | 1.23 % | $ 266 M | ||
|
OrganiGram Holdings
OGI
|
456 M | $ 1.41 | 2.55 % | $ 402 M | ||
|
Emergent BioSolutions
EBS
|
1.2 B | $ 8.34 | 5.97 % | $ 427 M | ||
|
Pacira BioSciences
PCRX
|
1.68 B | $ 23.17 | 2.84 % | $ 1.07 B | ||
|
Sundial Growers
SNDL
|
-17.5 M | $ 1.37 | 4.2 % | $ 3.37 M | ||
|
Tilray
TLRY
|
1.96 B | $ 6.8 | 5.19 % | $ 4.2 B | ||
|
Solid Biosciences
SLDB
|
616 M | $ 7.92 | 2.33 % | $ 693 M | ||
|
Lannett Company
LCI
|
648 M | - | 1.15 % | $ 7.11 M | ||
|
Veru
VERU
|
111 M | $ 2.54 | 2.42 % | $ 343 M | ||
|
Viatris
VTRS
|
41.3 B | $ 13.63 | 3.57 % | $ 16.4 B | ||
|
OptiNose
OPTN
|
312 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
73.8 M | - | -27.8 % | $ 2.56 M | ||
|
cbdMD
YCBD
|
7.85 M | $ 0.71 | 1.83 % | $ 3.06 M | ||
|
Relmada Therapeutics
RLMD
|
251 M | $ 6.9 | 2.22 % | $ 272 M | ||
|
Rockwell Medical
RMTI
|
43.3 M | $ 0.94 | -0.61 % | $ 33.8 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
7.57 M | $ 2.31 | 4.52 % | $ 2.87 M | ||
|
SCYNEXIS
SCYX
|
26.3 M | $ 0.95 | -0.77 % | $ 47.4 M | ||
|
Zomedica Corp.
ZOM
|
2.62 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-22.6 M | - | - | $ 55.5 M | ||
|
Tricida
TCDA
|
506 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
10.7 M | $ 0.61 | 0.11 % | $ 2.62 M | ||
|
TherapeuticsMD
TXMD
|
26.3 M | $ 2.13 | 5.69 % | $ 24.6 M |